Help us improve your experience. Please confirm your investor type:
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

Advertisement

The fields of Life Sciences have gone through a set of transformations during the past decades. Genomic technologies are generating an extraordinary amount of information, unprecedented in the history of biology. With the rise of bioinformatics and computational biology, data acquisition and integration have become increasingly important in drug discovery, personalized medicine, preventative medicine and gene therapy.
This fusion between science and technology has put bioengineering at the forefront of scientific discovery, creating innovative medical devices, vaccines, disease management products, robots, and algorithms that improve human health around the world.
With friendlier regulations and less scrutiny, health practitioners are prescribing more natural products such as cannabis to treat patients' chronic pains and other illnesses. The legalization of medical marijuana in Canada and several US states has pushed the value of the medical marijuana market to more than USD 20 billion in 2020 and it is expected to grow as more states follow suit. In addition to marijuana, promising studies and destigmatization are making psychedelics an increasingly viable treatment for mental illness and behavioural issues such as depression, anxiety and addiction among other.
The biotechnological breakthroughs of the future will attract more investments in the multi-trillion-dollar healthcare space and deliver miracle-like treatments of the world's peskiest and most lethal diseases. Cancer will hopefully meet its match with advancing immunotherapy and orphan drugs will become more effective to cure more than 7,000 rare diseases affecting millions of people worldwide.
Price | 1M returns* | ||
|---|---|---|---|
1ARKG | $3.55 | 1M returns* +31.40% | |
ARKG | $43.52 | 1M returns* +31.28% | |
AAKG | $8.16 | 1M returns* +30.70% | |
BBC | $52.87 | 1M returns* +29.22% | |
SBIO | $64.74 | 1M returns* +28.78% | |
GNMX | $32.29 | 1M returns* +24.59% | |
GNOM | $58.72 | 1M returns* +23.04% | |
GNOG | $10.47 | 1M returns* +23.00% | |
LFSC | $46.36 | 1M returns* +22.46% | |
WDNA | $21.24 | 1M returns* +20.13% |
Advertisement
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about Trackinsight